MAL2 and hepatocellular carcinoma: Additionally, our autophagy-inducing peptides offer possible pharmacological strategies to overcome such IL7/MAL2-mediated drug resistance and enhance the therapeutic effect of existing drugs like Sorafenib in devastating diseases like HCC.